GH Research Announces AGM and Key Resolutions for July 2025

GH Research ( (GHRS) ) has provided an update.

On June 18, 2025, GH Research PLC announced the convening of its annual general meeting (AGM) scheduled for July 31, 2025, in Dublin, Ireland. The AGM will address several key resolutions, including the re-election of directors and the renewal of share issuance authorities. The renewal of these authorities is crucial for the company to maintain its flexibility in raising capital, which is essential for its ongoing development and competitive positioning in the biopharmaceutical sector. Shareholders will also review the 2024 Irish statutory financial statements audited by PricewaterhouseCoopers Ireland.

The most recent analyst rating on (GHRS) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.

Spark’s Take on GHRS Stock

According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.

GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.

To see Spark’s full report on GHRS stock, click here.

More about GH Research

GH Research PLC is a clinical-stage biopharmaceutical company based in Ireland, focused on the development and commercialization of innovative therapies. The company is listed on Nasdaq and operates within the biopharmaceutical industry, requiring significant capital investment for research and development activities.

Average Trading Volume: 181,657

Technical Sentiment Signal: Strong Buy

Current Market Cap: $789M

Learn more about GHRS stock on TipRanks’ Stock Analysis page.